Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript

Pulmonx Corporation (NASDAQ:LUNG) Q2 2025 Earnings Conference Call July 30, 2025 4:30 AM ET

Company Participants

Mehul Joshi - Chief Financial Officer
Steven S. Williamson - CEO, President & Director

Conference Call Participants

Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division
Frederick Allen Wise - Stifel, Nicolaus & Company, Incorporated, Research Division
Jeremy Feffer - Lifesci Advisors, LLC

Operator

Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Jeremy Feffer of LifeSci Advisors Investor Relations. Please go ahead.

Jeremy Feffer

Good afternoon, and thank you all for participating in today's call. Joining me from Pulmonx this afternoon are Steve Williamson, President and Chief Executive Officer; and Mehul Joshi, Chief Financial Officer.

Earlier today, Pulmonx issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is available on Pulmonx's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements, including, without limitation, those relating to the company's operating trends, commercial strategies and future financial performance, the timing and results of clinical trials, expense management, market opportunity, guidance for revenue, gross margin and operating expenses, commercial expansion and product demand, adoption and pipeline development are based on our current estimates and various assumptions.

Forward-looking statements